Noninvasive, Uniplex, Molecular, Pathomic Urinary Assay for Detection of Prostate Cancer
用于检测前列腺癌的无创、单一、分子、病理性尿液分析
基本信息
- 批准号:9975980
- 负责人:
- 金额:$ 70.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AdvocateAttentionBenignBenign Prostatic HypertrophyBiochemistryBiological AssayBiological MarkersBiopsyBlindedBloodBreastCancer EtiologyCancer PatientCellsCessation of lifeClinicalDevelopmentDiagnosisDiagnosticDiagnostic testsDigital Rectal ExaminationDiseaseFDA approvedFingersFluorescenceGenomicsGoalsGoldHOXC6 geneHealthcareHistologyHumanImageIndolentInvestigationLabelLifeLiteratureMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMessenger RNAMethodsMolecularMolecular ProfilingMorbidity - disease rateNamesNorth AmericaPathologyPatientsPeptidesPredictive ValueProceduresProstateProstate-Specific AntigenProteinsResearch PersonnelRoleSamplingScheduleScreening for Prostate CancerSensitivity and SpecificitySerologicalSerumSolidSpecificitySurfaceTestingTranslatingTransrectal UltrasoundUltrasonographyUnited States National Institutes of HealthUrinecancer biomarkerscancer cellcancer diagnosisclinical practicedesigndiagnostic biomarkerfluorophorein vivoinnovationmalignant breast neoplasmmenminimally invasivenoveloptical imagingoverexpressionovertreatmentprostate biopsyprostate cancer cellreceptorserum PSAstemtumor molecular fingerprinturinaryvasoactive intestinal peptide receptor 1
项目摘要
Abstract: Despite the advances in understanding its genomic and molecular basis, prostate cancer (PCa)
remains the most commonly diagnosed solid malignancy in men in the US and the second leading cause of cancer
death. Currently, the only established method to diagnose PCa is an invasive transrectal ultrasound prostate
biopsy. The majority (>66%) of biopsies show benign pathology at the expense of patient morbidity and
healthcare dollars. There remains, therefore, an unmet need for a simple and non-invasive approach that will
definitively diagnose PCa, determine if it is aggressive, indolent or benign and help guide its management.
The era of molecular profiling has drawn much attention to genomic analysis of malignant PCa cells shed in blood
and urine. In two such assays, the PCA3 and SelectMDx approved by FDA, urine is collected after DRE, malignant
cells isolated and characterized by multiplex genomic finger prints of PCa. Although innovative, PCA3 test is not
widely used, primarily due to its wide range (62%-94%) of sensitivity, specificity, positive predictive (PPV) and
negative predictive value (NPV). Furthermore, the clinical utility of SelectMDx and a frequently advocated serum
4Kscore test, remains uncertain.
There is robust literature demonstrating that VPAC receptors are expressed on PCa cells. With NIH/NCI
support, we designed and labeled a VPAC specific peptide with Cu-64 that allowed us to image PCa successfully in
humans. We then hypothesized that PCa cells, shed in voided urine of PCa patients, without prostate stimulation
by DRE, can be imaged optically by targeting VPAC receptors, using the same peptide labeled with a
fluorophore. Our preliminary results of >250 de-identified urine samples, collected from patients with PCa, BPH
and normal cases, are encouraging (sensitivity >98%) and are consistent with our hypothesis. In this investigation
we propose to obtain critical information that will be required for the development of this promising noninvasive
urine assay as a PCa diagnostic test. Our specific aims are 1) To determine sensitivity, specificity, positive
predictive (PPV), and negative predictive value (NPV) of the molecular urinary assay for men with known
PCa and negative controls; 2) To examine the efficacy of the assay in the management of patients with
previous negative biopsy for PCa but have persistently elevated PSA and are scheduled for TRUS biopsy;
3) To establish if a) the malignant cells as a percent of total cells shed in the urine, b) the fluorescence
intensity around malignant cells, and c) the VPAC protein quantity in shed malignant cells correlate with
the aggressiveness of the disease; 4) To assess the role of this molecular urine assay in the management
patients on active surveillance; and 5) To determine if a preservative is required for urine storage. This
simple, reliable and patient-friendly uniplex assay will a) detect active, aggressive or indolent PCa, b) save patients
from over diagnosis and over treatment, c) reduce the number of unnecessary biopsies and associated patient
morbidity, and d) save millions of healthcare dollars.
翻译后摘要:尽管在了解其基因组和分子基础的进展,前列腺癌(PCa)
仍然是美国男性中最常诊断的实体恶性肿瘤,也是癌症的第二大原因
死亡目前,诊断PCa的唯一方法是侵入性经直肠前列腺超声
活检大多数(>66%)活检显示良性病变,但患者发病率较高,
医疗保健美元因此,仍然需要一种简单且非侵入性的方法,
明确诊断PCa,确定它是侵袭性的,惰性的还是良性的,并帮助指导其管理。
随着分子生物学的发展,血液中PCa细胞的基因组分析受到了广泛的关注
和尿液。在两种这样的测定中,FDA批准的PCA 3和SelectMDx,在DRE后收集尿液,恶性肿瘤
细胞分离和PCa的多重基因组指纹特征。PCA 3测试虽然具有创新性,
广泛使用,主要是由于其灵敏度、特异性、阳性预测(PPV)和
阴性预测值(NPV)。此外,SelectMDx和一种经常提倡的血清的临床效用
4Kscore测试,仍不确定。
有大量文献证明VPAC受体在PCa细胞上表达。关于NIH/NCI
支持,我们设计并标记了VPAC特异性肽与Cu-64,使我们能够成像PCa成功地在
人类然后我们假设,在没有前列腺刺激的情况下,PCa患者排尿中脱落的PCa细胞,
通过DRE,可以通过靶向VPAC受体进行光学成像,使用标记有
荧光团。我们对从PCa、BPH患者中收集的>250份去识别尿液样本的初步结果
和正常情况下,是令人鼓舞的(灵敏度>98%),并与我们的假设一致。在这次调查中
我们建议获得发展这种有前途的非侵入性技术所需的关键信息,
尿分析作为PCa诊断测试。我们的具体目标是1)确定灵敏度,特异性,阳性
预测值(PPV)和阴性预测值(NPV)的分子尿测定男性已知
PCa和阴性对照; 2)检查该测定法在管理PCa患者中的有效性,
既往PCa活检阴性,但PSA持续升高,计划进行TRUS活检;
3)为了确定是否a)恶性细胞占尿中脱落的总细胞的百分比,B)荧光
c)脱落的恶性细胞中的VPAC蛋白质量与恶性细胞周围的VPAC蛋白质强度相关,
4)评估这种分子尿检测在治疗中的作用,
积极监测的患者;和5)确定尿液储存是否需要防腐剂。这
简单、可靠和患者友好的单重测定将a)检测活动性、侵袭性或惰性PCa,B)挽救患者
c)减少不必要的活检和相关患者的数量
d)节省数百万美元的医疗费用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MATHEW laxman THAKUR其他文献
MATHEW laxman THAKUR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MATHEW laxman THAKUR', 18)}}的其他基金
Noninvasive, Uniplex, Molecular, Pathomic Urinary Assay for Detection of Prostate Cancer
用于检测前列腺癌的无创、单一、分子、病理性尿液分析
- 批准号:
10663194 - 财政年份:2020
- 资助金额:
$ 70.06万 - 项目类别:
Noninvasive, Uniplex, Molecular, Pathomic Urinary Assay for Detection of Prostate Cancer
用于检测前列腺癌的无创、单一、分子、病理性尿液分析
- 批准号:
10249302 - 财政年份:2020
- 资助金额:
$ 70.06万 - 项目类别:
Noninvasive, Uniplex, Molecular, Pathomic Urinary Assay for Detection of Prostate Cancer
用于检测前列腺癌的无创、单一、分子、病理性尿液分析
- 批准号:
10427409 - 财政年份:2020
- 资助金额:
$ 70.06万 - 项目类别:
SPECT/CT for Molecular Imaging Facility at TJU
TJU 分子成像设备 SPECT/CT
- 批准号:
8628246 - 财政年份:2014
- 资助金额:
$ 70.06万 - 项目类别:
VPAC1 Recpetor-Targeted PET Imaging of Prostate Cancer
VPAC1 受体靶向前列腺癌 PET 成像
- 批准号:
8661713 - 财政年份:2012
- 资助金额:
$ 70.06万 - 项目类别:
VPAC1 Recpetor-Targeted PET Imaging of Prostate Cancer
VPAC1 受体靶向前列腺癌 PET 成像
- 批准号:
8242429 - 财政年份:2012
- 资助金额:
$ 70.06万 - 项目类别:
VPAC1 Recpetor-Targeted PET Imaging of Prostate Cancer
VPAC1 受体靶向前列腺癌 PET 成像
- 批准号:
8925008 - 财政年份:2012
- 资助金额:
$ 70.06万 - 项目类别:
VPAC1 Recpetor-Targeted PET Imaging of Prostate Cancer
VPAC1 受体靶向前列腺癌 PET 成像
- 批准号:
9247760 - 财政年份:2012
- 资助金额:
$ 70.06万 - 项目类别:
VPAC1 Recpetor-Targeted PET Imaging of Prostate Cancer
VPAC1 受体靶向前列腺癌 PET 成像
- 批准号:
8461116 - 财政年份:2012
- 资助金额:
$ 70.06万 - 项目类别:
相似国自然基金
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
Development of social attention indicators of emerging technologies and science policies with network analysis and text mining
利用网络分析和文本挖掘开发新兴技术和科学政策的社会关注指标
- 批准号:
24K16438 - 财政年份:2024
- 资助金额:
$ 70.06万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Improving Flexible Attention to Numerical and Spatial Magnitudes in Young Children
提高幼儿对数字和空间大小的灵活注意力
- 批准号:
2410889 - 财政年份:2024
- 资助金额:
$ 70.06万 - 项目类别:
Continuing Grant
The Information-Attention Tradeoff: Toward an Understanding of the Fundamentals of Online Attention
信息与注意力的权衡:了解在线注意力的基本原理
- 批准号:
2343858 - 财政年份:2024
- 资助金额:
$ 70.06万 - 项目类别:
Continuing Grant
The everyday learning opportunities of young children with attention and motor difficulties: From understanding constraints to reshaping intervention
注意力和运动困难幼儿的日常学习机会:从理解限制到重塑干预
- 批准号:
MR/X032922/1 - 财政年份:2024
- 资助金额:
$ 70.06万 - 项目类别:
Fellowship
Towards a cognitive process model of how attention and choice interact
建立注意力和选择如何相互作用的认知过程模型
- 批准号:
DP240102605 - 财政年份:2024
- 资助金额:
$ 70.06万 - 项目类别:
Discovery Projects
DDRIG in DRMS: Communicating risks in a sensational media environment-Using short video multimodal features to attract attention and reduce psychological reactance for persuasion
DRMS中的DDRIG:耸人听闻的媒体环境中沟通风险——利用短视频多模态特征吸引注意力,减少说服心理抵触
- 批准号:
2343506 - 财政年份:2024
- 资助金额:
$ 70.06万 - 项目类别:
Standard Grant
Assessing the Influence of Reading Fiction on Multiple Tests of Attention
评估阅读小说对注意力多重测试的影响
- 批准号:
24K16033 - 财政年份:2024
- 资助金额:
$ 70.06万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
CAREER: Designing Ultra-Energy-Efficient Intelligent Hardware with On-Chip Learning, Attention, and Inference
职业:设计具有片上学习、注意力和推理功能的超节能智能硬件
- 批准号:
2336012 - 财政年份:2023
- 资助金额:
$ 70.06万 - 项目类别:
Continuing Grant
CPS: Small: Brain-Inspired Memorization and Attention for Intelligent Sensing
CPS:小:智能传感的受大脑启发的记忆和注意力
- 批准号:
2312517 - 财政年份:2023
- 资助金额:
$ 70.06万 - 项目类别:
Standard Grant
CAREER: Understanding the Relationship of Covert and Overt Attention Using Concurrent EEG and Eye Tracking
职业:使用并发脑电图和眼动追踪了解隐性注意力和显性注意力的关系
- 批准号:
2345898 - 财政年份:2023
- 资助金额:
$ 70.06万 - 项目类别:
Continuing Grant